ARTICLE | Company News
AVI, Lorus deal
July 17, 2000 7:00 AM UTC
The companies will co-develop antisense compounds to treat cancer and infectious diseases under a five-year deal. AVII will contribute its Neugene antisense backbone technology, while LOR will provide...